Top

Published in:

01-03-2020 | Glioblastoma

Drug repurposing towards targeting cancer stem cells in pediatric brain tumors

Authors: Hisham F. Bahmad, Mohamad K. Elajami, Talal El Zarif, Jolie Bou-Gharios, Tamara Abou-Antoun, Wassim Abou-Kheir

Published in: Cancer and Metastasis Reviews | Issue 1/2020

Abstract

In the pediatric population, brain tumors represent the most commonly diagnosed solid neoplasms and the leading cause of cancer-related deaths globally. They include low-grade gliomas (LGGs), medulloblastomas (MBs), and other embryonal, ependymal, and neuroectodermal tumors. The mainstay of treatment for most brain tumors includes surgical intervention, radiation therapy, and chemotherapy. However, resistance to conventional therapy is widespread, which contributes to the high mortality rates reported and lack of improvement in patient survival despite advancement in therapeutic research. This has been attributed to the presence of a subpopulation of cells, known as cancer stem cells (CSCs), which reside within the tumor bulk and maintain self-renewal and recurrence potential of the tumor. An emerging promising approach that enables identifying novel therapeutic strategies to target CSCs and overcome therapy resistance is drug repurposing or repositioning. This is based on using previously approved drugs with known pharmacokinetic and pharmacodynamic characteristics for indications other than their traditional ones, like cancer. In this review, we provide a synopsis of the drug repurposing methodologies that have been used in pediatric brain tumors, and we argue how this selective compilation of approaches, with a focus on CSC targeting, could elevate drug repurposing to the next level.

Pollack, I. F., & Jakacki, R. I. (2011). Childhood brain tumors: epidemiology, current management and future directions. Nature Reviews Neurology, 7(9), 495–506. https://doi.org/10.1038/nrneurol.2011.110.CrossRefPubMed

Pollack, I. F. (1994). Brain tumors in children. New England Journal of Medicine, 331(22), 1500–1507. https://doi.org/10.1056/nejm199412013312207.CrossRefPubMed

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a Cancer Journal for Clinicians, 69(1), 7–34. https://doi.org/10.3322/caac.21551.CrossRef

Smith, M. A., & Reaman, G. H. (2015). Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatric Clinics of North America, 62(1), 301–312. https://doi.org/10.1016/j.pcl.2014.09.018.CrossRefPubMed

Jones, D. T. W., Kieran, M. W., Bouffet, E., Alexandrescu, S., Bandopadhayay, P., Bornhorst, M., et al. (2018). Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 20(2), 160–173. https://doi.org/10.1093/neuonc/nox141.CrossRefPubMed

Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., et al. (2019). Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 16(8), 509–520. https://doi.org/10.1038/s41571-019-0177-5.CrossRefPubMedPubMedCentral

Mackay, A., Burford, A., Carvalho, D., Izquierdo, E., Fazal-Salom, J., Taylor, K. R., et al. (2017). Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell, 32(4), 520–537.e525. https://doi.org/10.1016/j.ccell.2017.08.017.CrossRefPubMedPubMedCentral

Quail, D. F., & Joyce, J. A. (2017). The microenvironmental landscape of brain tumors. Cancer Cell, 31(3), 326–341. https://doi.org/10.1016/j.ccell.2017.02.009.CrossRefPubMedPubMedCentral

Gilbertson, R. J. (2011). Mapping cancer origins. Cell, 145(1), 25–29. https://doi.org/10.1016/j.cell.2011.03.019.CrossRefPubMedPubMedCentral

10.

Abou-Antoun, T. J., Hale, J. S., Lathia, J. D., & Dombrowski, S. M. (2017). Brain cancer stem cells in adults and children: cell biology and therapeutic implications. Neurotherapeutics, 14(2), 372–384. https://doi.org/10.1007/s13311-017-0524-0.CrossRefPubMedPubMedCentral

11.

Bahmad, H. F., Chamaa, F., Assi, S., Chalhoub, R. M., Abou-Antoun, T., & Abou-Kheir, W. (2019). Cancer stem cells in neuroblastoma: expanding the therapeutic frontier. Frontiers in Molecular Neuroscience, 12, 131. https://doi.org/10.3389/fnmol.2019.00131.CrossRefPubMedPubMedCentral

12.

Bahmad, H. F., & Poppiti, R. J. (submitted). Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets. Journal of Clinical Pathology.

13.

Lathia, J. D. (2013). Cancer stem cells: moving past the controversy. CNS Oncol, 2(6), 465–467. https://doi.org/10.2217/cns.13.42.CrossRefPubMedPubMedCentral

14.

Nowak-Sliwinska, P., Scapozza, L., & Altaba, A. R. I. (2019). Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochimica et biophysica acta. Reviews on cancer, 1871(2), 434–454, https://doi.org/10.1016/j.bbcan.2019.04.005.

15.

Hernandez, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., et al. (2017). Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as Cancer therapeutics. Frontiers in Oncology, 7, 273. https://doi.org/10.3389/fonc.2017.00273.CrossRefPubMedPubMedCentral

16.

Bhat-Nakshatri, P., Goswami, C. P., Badve, S., Sledge Jr., G. W., & Nakshatri, H. (2013). Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Scientific Reports, 3, 2530. https://doi.org/10.1038/srep02530.CrossRefPubMedPubMedCentral

17.

Tan, S. K., Jermakowicz, A., Mookhtiar, A. K., Nemeroff, C. B., Schürer, S. C., & Ayad, N. G. (2018). Drug repositioning in glioblastoma: a pathway perspective. [review]. Front Pharmacol, 9(218). https://doi.org/10.3389/fphar.2018.00218.

18.

Pui, C.-H., Gajjar, A. J., Kane, J. R., Qaddoumi, I. A., & Pappo, A. S. (2011). Challenging issues in pediatric oncology. Nature Reviews Clinical Oncology, 8(9), 540–549. https://doi.org/10.1038/nrclinonc.2011.95.CrossRefPubMedPubMedCentral

19.

National Cancer Institute. (2010). Surveillance, epidemiology and end results (pp. 1975–2007). SEER Cancer Statistics Review: Previous Version http://seer.cancer.gov/csr/.

20.

Corsello, S. M., Bittker, J. A., Liu, Z., Gould, J., McCarren, P., Hirschman, J. E., et al. (2017). The drug repurposing hub: a next-generation drug library and information resource. Nature Medicine, 23(4), 405–408. https://doi.org/10.1038/nm.4306.CrossRefPubMedPubMedCentral

21.

Minturn, J. E., & Fisher, M. J. (2013). Gliomas in children. Current Treatment Options in Neurology, 15(3), 316–327. https://doi.org/10.1007/s11940-013-0225-x.CrossRefPubMed

22.

Sievert, A. J., & Fisher, M. J. (2009). Pediatric low-grade gliomas. Journal of Child Neurology, 24(11), 1397–1408. https://doi.org/10.1177/0883073809342005.CrossRefPubMedPubMedCentral

23.

El-Ayadi, M., Ansari, M., Sturm, D., Gielen, G. H., Warmuth-Metz, M., Kramm, C. M., et al. (2017). High-grade glioma in very young children: a rare and particular patient population. Oncotarget, 8(38), 64564–64578. https://doi.org/10.18632/oncotarget.18478.CrossRefPubMedPubMedCentral

24.

Sturm, D., Pfister, S. M., & Jones, D. T. W. (2017). Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. Journal of Clinical Oncology, 35(21), 2370–2377. https://doi.org/10.1200/JCO.2017.73.0242.CrossRefPubMed

25.

Miyashita, K., Kawakami, K., Nakada, M., Mai, W., Shakoori, A., Fujisawa, H., et al. (2009). Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Clinical Cancer Research, 15(3), 887–897. https://doi.org/10.1158/1078-0432.CCR-08-0760.CrossRefPubMed

26.

Nam, J. Y., & de Groot, J. F. (2017). Treatment of glioblastoma. Journal of Oncology Practice/ American Society of Clinical Oncology, 13(10), 629–638. https://doi.org/10.1200/JOP.2017.025536.CrossRef

27.

Xu, H. S., Qin, X. L., Zong, H. L., He, X. G., & Cao, L. (2017). Cancer stem cell markers in glioblastoma—an update. European Review for Medical and Pharmacological Sciences, 21(14), 3207–3211.PubMed

28.

Singh, S. K., Clarke, I. D., Hide, T., & Dirks, P. B. (2004). Cancer stem cells in nervous system tumors. Oncogene, 23(43), 7267–7273. https://doi.org/10.1038/sj.onc.1207946.CrossRefPubMed

29.

Abbruzzese, C., Matteoni, S., Signore, M., Cardone, L., Nath, K., Glickson, J. D., et al. (2017). Drug repurposing for the treatment of glioblastoma multiforme. Journal of Experimental & Clinical Cancer Research, 36(1), 169. https://doi.org/10.1186/s13046-017-0642-x.CrossRef

30.

Wang, Y., Meng, Y., Zhang, S., Wu, H., Yang, D., Nie, C., et al. (2018). Phenformin and metformin inhibit growth and migration of LN229 glioma cells in vitro and in vivo. Onco Targets Ther, 11, 6039–6048. https://doi.org/10.2147/OTT.S168981.CrossRefPubMedPubMedCentral

31.

Jiang, W., Finniss, S., Cazacu, S., Xiang, C., Brodie, Z., Mikkelsen, T., et al. (2016). Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget, 7(35), 56456–56470. https://doi.org/10.18632/oncotarget.10919.CrossRefPubMedPubMedCentral

32.

Koyuturk, M., Ersoz, M., & Altiok, N. (2004). Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neuroscience Letters, 370(2–3), 212–217. https://doi.org/10.1016/j.neulet.2004.08.020.CrossRefPubMed

33.

Xiao, A., Brenneman, B., Floyd, D., Comeau, L., Spurio, K., Olmez, I., et al. (2019). Statins affect human glioblastoma and other cancers through TGF-beta inhibition. Oncotarget, 10(18), 1716–1728. https://doi.org/10.18632/oncotarget.26733.CrossRefPubMedPubMedCentral

34.

Pinter, M., & Jain, R. K. (2017). Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Science Translational Medicine, 9(410). https://doi.org/10.1126/scitranslmed.aan5616.

35.

Kitabayashi, T., Dong, Y., Furuta, T., Sabit, H., Jiapaer, S., Zhang, J., et al. (2019). Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Scientific Reports, 9(1), 10049. https://doi.org/10.1038/s41598-019-46454-8.CrossRefPubMedPubMedCentral

36.

Handley, M. V. (2015). GSK-3 inhibitors in glioblastoma therapy: mechanisms of action. BOSTON UNIVERSITY.

37.

Nowicki, M. O., Dmitrieva, N., Stein, A. M., Cutter, J. L., Godlewski, J., Saeki, Y., et al. (2008). Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro-Oncology, 10(5), 690–699. https://doi.org/10.1215/15228517-2008-041.CrossRefPubMedPubMedCentral

38.

Chirasani, S. R., Leukel, P., Gottfried, E., Hochrein, J., Stadler, K., Neumann, B., et al. (2013). Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. International Journal of Cancer, 132(4), 843–853. https://doi.org/10.1002/ijc.27712.CrossRefPubMed

39.

Leidgens, V., Seliger, C., Jachnik, B., Welz, T., Leukel, P., Vollmann-Zwerenz, A., et al. (2015). Ibuprofen and diclofenac restrict migration and proliferation of human glioma cells by distinct molecular mechanisms. PLoS One, 10(10), e0140613. https://doi.org/10.1371/journal.pone.0140613.CrossRefPubMedPubMedCentral

40.

Tuettenberg, J., Grobholz, R., Korn, T., Wenz, F., Erber, R., & Vajkoczy, P. (2005). Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. Journal of Cancer Research and Clinical Oncology, 131(1), 31–40. https://doi.org/10.1007/s00432-004-0620-5.CrossRefPubMed

41.

Johannessen, T. C., Hasan-Olive, M. M., Zhu, H., Denisova, O., Grudic, A., Latif, M. A., et al. (2019). Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. International Journal of Cancer, 144(7), 1735–1745. https://doi.org/10.1002/ijc.31912.CrossRefPubMed

42.

Kang, S., Lee, J. M., Jeon, B., Elkamhawy, A., Paik, S., Hong, J., et al. (2018). Repositioning of the antipsychotic trifluoperazine: synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents. European Journal of Medicinal Chemistry, 151, 186–198. https://doi.org/10.1016/j.ejmech.2018.03.055.CrossRefPubMed

43.

Hayashi, K., Michiue, H., Yamada, H., Takata, K., Nakayama, H., Wei, F. Y., et al. (2016). Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Scientific Reports, 6, 23372. https://doi.org/10.1038/srep23372.CrossRefPubMedPubMedCentral

44.

Al Hassan, M., Fakhoury, I., El Masri, Z., Ghazale, N., Dennaoui, R., El Atat, O., et al. (2018). Metformin treatment inhibits motility and invasion of glioblastoma cancer cells. Analytical Cellular Pathology, 2018, 9. https://doi.org/10.1155/2018/5917470.CrossRef

45.

Oesterle, A., Laufs, U., & Liao, J. K. (2017). Pleiotropic effects of statins on the cardiovascular system. Circulation Research, 120(1), 229–243. https://doi.org/10.1161/CIRCRESAHA.116.308537.CrossRefPubMedPubMedCentral

46.

Shojaei, S., Alizadeh, J., Thliveris, J., Koleini, N., Kardami, E., Hatch, G. M., et al. (2018). Statins: a new approach to combat temozolomide chemoresistance in glioblastoma. Journal of Investigative Medicine, 66(8), 1083–1087. https://doi.org/10.1136/jim-2018-000874.CrossRefPubMed

47.

Rasmussen, E. R., Pottegard, A., Bygum, A., von Buchwald, C., Homoe, P., & Hallas, J. (2019). Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study. Journal of Internal Medicine, 285(5), 553–561. https://doi.org/10.1111/joim.12867.CrossRefPubMed

48.

Barreras, A., & Gurk-Turner, C. (2003). Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent), 16(1), 123–126. https://doi.org/10.1080/08998280.2003.11927893.CrossRef

49.

Ino, K., Shibata, K., Kajiyama, H., Yamamoto, E., Nagasaka, T., Nawa, A., et al. (2006). Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. British Journal of Cancer, 94(4), 552–560. https://doi.org/10.1038/sj.bjc.6602961.CrossRefPubMedPubMedCentral

50.

Arrieta, O., Villarreal-Garza, C., Vizcaino, G., Pineda, B., Hernandez-Pedro, N., Guevara-Salazar, P., et al. (2015). Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumour Biology, 36(7), 5627–5634. https://doi.org/10.1007/s13277-015-3235-3.CrossRefPubMed

51.

Rocken, C., Rohl, F. W., Diebler, E., Lendeckel, U., Pross, M., Carl-McGrath, S., et al. (2007). The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiology, Biomarkers & Prevention, 16(6), 1206–1212. https://doi.org/10.1158/1055-9965.epi-05-0934.CrossRef

52.

Feng, E., Sui, C., Wang, T., & Sun, G. (2017). Temozolomide with or without radiotherapy in patients with newly diagnosed glioblastoma Multiforme: a meta-analysis. European Neurology, 77(3–4), 201–210. https://doi.org/10.1159/000455842.CrossRefPubMed

53.

Ghaffari, S. (2011). Cancer, stem cells and cancer stem cells: old ideas, new developments. F1000 Med Rep, 3, 23. https://doi.org/10.3410/M3-23.CrossRefPubMedPubMedCentral

54.

Nakada M., M. T, Pyko I., Hayashi Y. and Hamada J. (2011). The pivotal roles of GSK3β in glioma biology In M. Garami (Ed.), Molecular Targets of CNS Tumors IntechOpen.

55.

Vashishtha, V., Jinghan, N., & A, K. Y. (2018). Antagonistic role of GSK3 isoforms in glioma survival. Journal of Cancer, 9(10), 1846–1855. https://doi.org/10.7150/jca.21248.

56.

Llorens-Martin, M., Jurado, J., Hernandez, F., & Avila, J. (2014). GSK-3beta, a pivotal kinase in Alzheimer disease. Frontiers in Molecular Neuroscience, 7, 46. https://doi.org/10.3389/fnmol.2014.00046.CrossRefPubMed

57.

del Ser, T., Steinwachs, K. C., Gertz, H. J., Andres, M. V., Gomez-Carrillo, B., Medina, M., et al. (2013). Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study. Journal of Alzheimer's Disease, 33(1), 205–215. https://doi.org/10.3233/JAD-2012-120805.CrossRefPubMed

58.

Tolosa, E., Litvan, I., Hoglinger, G. U., Burn, D., Lees, A., Andres, M. V., et al. (2014). A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders, 29(4), 470–478. https://doi.org/10.1002/mds.25824.CrossRefPubMed

59.

Lovestone, S., Boada, M., Dubois, B., Hull, M., Rinne, J. O., Huppertz, H. J., et al. (2015). A phase II trial of tideglusib in Alzheimer’s disease. Journal of Alzheimer's Disease, 45(1), 75–88. https://doi.org/10.3233/jad-141959.CrossRefPubMed

60.

Mathuram, T. L., Ravikumar, V., Reece, L. M., Karthik, S., Sasikumar, C. S., & Cherian, K. M. (2016). Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation. Environmental Toxicology and Pharmacology, 46, 194–205. https://doi.org/10.1016/j.etap.2016.07.013.CrossRefPubMed

61.

Zhou, A., Lin, K., Zhang, S., Chen, Y., Zhang, N., Xue, J., et al. (2016). Nuclear GSK3beta promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nature Cell Biology, 18(9), 954–966. https://doi.org/10.1038/ncb3396.CrossRefPubMedPubMedCentral

62.

Chalhoub, R. M., Bahmad, H. F., Harati, H., Assi, S., Araji, T., Bou-Gharios, J., et al. (2019). Specific inhibition of GSK-3β by Tideglusib: potential therapeutic target for neuroblastoma cancer stem cells. Submitted.

63.

Hata, A. N., & Breyer, R. M. (2004). Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology & Therapeutics, 103(2), 147–166. https://doi.org/10.1016/j.pharmthera.2004.06.003.CrossRef

64.

Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., et al. (2003). Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. The Journal of Experimental Medicine, 197(2), 221–232. https://doi.org/10.1084/jem.20021408.CrossRefPubMedPubMedCentral

65.

Seliger, C., & Hau, P. (2018). Drug repurposing of metabolic agents in malignant glioma. International Journal of Molecular Sciences, 19(9). https://doi.org/10.3390/ijms19092768.

66.

Li, J., Kim, S. G., & Blenis, J. (2014). Rapamycin: One drug, many effects. Cell Metabolism, 19(3), 373–379. https://doi.org/10.1016/j.cmet.2014.01.001.CrossRefPubMedPubMedCentral

67.

Yang, Z., Hackshaw, A., Feng, Q., Fu, X., Zhang, Y., Mao, C., et al. (2017). Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. International Journal of Cancer, 140(12), 2805–2819. https://doi.org/10.1002/ijc.30691.CrossRefPubMed

68.

Yalon, M., Rood, B., MacDonald, T. J., McCowage, G., Kane, R., Constantini, S., et al. (2013). A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatric Blood & Cancer, 60(1), 71–76. https://doi.org/10.1002/pbc.24142.CrossRef

69.

Mollashahi, B., Aghamaleki, F. S., & Movafagh, A. (2019). The roles of miRNAs in medulloblastoma: a systematic review. J Cancer Prev, 24(2), 79–90. https://doi.org/10.15430/jcp.2019.24.2.79.CrossRefPubMedPubMedCentral

70.

Zulch, K. J. (1980). Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology, 19(2), 59–66. https://doi.org/10.1007/bf00342596.CrossRefPubMed

71.

DeAngelis, L. M. (2001). Brain tumors. The New England Journal of Medicine, 344(2), 114–123. https://doi.org/10.1056/nejm200101113440207.CrossRefPubMed

72.

Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442. https://doi.org/10.1038/415436a.CrossRefPubMed

73.

Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., et al. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology, 24(12), 1924–1931. https://doi.org/10.1200/jco.2005.04.4974.CrossRefPubMed

74.

Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., et al. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088. https://doi.org/10.1371/journal.pone.0003088.CrossRefPubMedPubMedCentral

75.

Cho, Y. J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., et al. (2011). Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology, 29(11), 1424–1430. https://doi.org/10.1200/jco.2010.28.5148.CrossRefPubMed

76.

Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., et al. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465–472. https://doi.org/10.1007/s00401-011-0922-z.CrossRefPubMed

77.

Thomas, A., & Noel, G. (2019). Medulloblastoma: optimizing care with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12, 335–347. https://doi.org/10.2147/jmdh.s167808.CrossRefPubMedPubMedCentral

78.

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756–760. https://doi.org/10.1038/nature05236.CrossRefPubMed

79.

Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., et al. (2004). Identification of human brain tumour initiating cells. Nature, 432(7015), 396–401. https://doi.org/10.1038/nature03128.CrossRefPubMed

80.

Abouantoun, T. J., Castellino, R. C., & MacDonald, T. J. (2011). Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. Journal of Neuro-Oncology, 101(2), 215–226. https://doi.org/10.1007/s11060-010-0259-9.CrossRefPubMed

81.

Abouantoun, T. J., & MacDonald, T. J. (2009). Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Molecular Cancer Therapeutics, 8(5), 1137–1147. https://doi.org/10.1158/1535-7163.mct-08-0889.CrossRefPubMedPubMedCentral

82.

Wolle, D., Lee, S. J., Li, Z., Litan, A., Barwe, S. P., & Langhans, S. A. (2014). Inhibition of epidermal growth factor signaling by the cardiac glycoside ouabain in medulloblastoma. Cancer Medicine, 3(5), 1146–1158. https://doi.org/10.1002/cam4.314.CrossRefPubMedPubMedCentral

83.

Huang, L., Garrett Injac, S., Cui, K., Braun, F., Lin, Q., Du, Y., et al. (2018). Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. Science Translational Medicine, 10(464). https://doi.org/10.1126/scitranslmed.aat0150.

84.

Takwi, A. A., Li, Y., Becker Buscaglia, L. E., Zhang, J., Choudhury, S., Park, A. K., et al. (2012). A statin-regulated microRNA represses human c-Myc expression and function. EMBO Molecular Medicine, 4(9), 896–909. https://doi.org/10.1002/emmm.201101045.CrossRefPubMedPubMedCentral

85.

Bar, E. E., Chaudhry, A., Farah, M. H., & Eberhart, C. G. (2007). Hedgehog signaling promotes medulloblastoma survival via Bc/II. The American Journal of Pathology, 170(1), 347–355. https://doi.org/10.2353/ajpath.2007.060066.CrossRefPubMedPubMedCentral

86.

Bar, E. E., & Stearns, D. (2008). New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination. Expert Opinion on Investigational Drugs, 17(2), 185–195. https://doi.org/10.1517/13543784.17.2.185.CrossRefPubMed

87.

Sheikholeslami, K., Ali Sher, A., Lockman, S., Kroft, D., Ganjibakhsh, M., Nejati-Koshki, K., et al. (2019). Simvastatin induces apoptosis in medulloblastoma brain tumor cells via mevalonate cascade prenylation substrates. Cancers (Basel), 11(7). https://doi.org/10.3390/cancers11070994.

88.

Bai, R. Y., Staedtke, V., Rudin, C. M., Bunz, F., & Riggins, G. J. (2015). Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology, 17(4), 545–554. https://doi.org/10.1093/neuonc/nou234.CrossRefPubMed

89.

Larsen, A. R., Bai, R. Y., Chung, J. H., Borodovsky, A., Rudin, C. M., Riggins, G. J., et al. (2015). Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Molecular Cancer Therapeutics, 14(1), 3–13. https://doi.org/10.1158/1535-7163.mct-14-0755-t.CrossRefPubMed

90.

Bell, J. B., Rink, J. S., Eckerdt, F., Clymer, J., Goldman, S., Thaxton, C. S., et al. (2018). HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. Scientific Reports, 8(1), 1211. https://doi.org/10.1038/s41598-017-18100-8.CrossRefPubMedPubMedCentral

91.

Rossi, A., Russo, G., Puca, A., La Montagna, R., Caputo, M., Mattioli, E., et al. (2009). The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. International Journal of Cancer, 125(1), 235–243. https://doi.org/10.1002/ijc.24331.CrossRefPubMedPubMedCentral

92.

Baryawno, N., Sveinbjornsson, B., Eksborg, S., Orrego, A., Segerstrom, L., Oqvist, C. O., et al. (2008). Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro-Oncology, 10(5), 661–674. https://doi.org/10.1215/15228517-2008-035.CrossRefPubMedPubMedCentral

93.

Yang, M. Y., Lee, H. T., Chen, C. M., Shen, C. C., & Ma, H. I. (2014). Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells. International Journal of Molecular Sciences, 15(6), 11013–11029. https://doi.org/10.3390/ijms150611013.CrossRefPubMedPubMedCentral

94.

Eslin, D., Lee, C., Sankpal, U. T., Maliakal, P., Sutphin, R. M., Abraham, L., et al. (2013). Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study. Tumour Biology, 34(5), 2781–2789. https://doi.org/10.1007/s13277-013-0836-6.CrossRefPubMed

95.

Kaplan, J. H. (2002). Biochemistry of Na,K-ATPase. Annual Review of Biochemistry, 71, 511–535. https://doi.org/10.1146/annurev.biochem.71.102201.141218.CrossRefPubMed

96.

Lingrel, J. B. (2010). The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na,K-ATPase. Annual Review of Physiology, 72, 395–412. https://doi.org/10.1146/annurev-physiol-021909-135725.CrossRefPubMedPubMedCentral

97.

Mijatovic, T., Van Quaquebeke, E., Delest, B., Debeir, O., Darro, F., & Kiss, R. (2007). Cardiotonic steroids on the road to anti-cancer therapy. Biochimica et Biophysica Acta, 1776(1), 32–57. https://doi.org/10.1016/j.bbcan.2007.06.002.CrossRefPubMed

98.

Yamada, M., Ikeuchi, T., & Hatanaka, H. (1997). The neurotrophic action and signalling of epidermal growth factor. Progress in Neurobiology, 51(1), 19–37.CrossRefPubMed

99.

Wong, R. W., & Guillaud, L. (2004). The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine & Growth Factor Reviews, 15(2–3), 147–156. https://doi.org/10.1016/j.cytogfr.2004.01.004.CrossRef

100.

Gilbertson, R. J., Perry, R. H., Kelly, P. J., Pearson, A. D., & Lunec, J. (1997). Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Research, 57(15), 3272–3280.PubMed

101.

Waage, I. S., Vreim, I., & Torp, S. H. (2013). C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview. International Journal of Surgical Pathology, 21(6), 573–582. https://doi.org/10.1177/1066896913492196.CrossRefPubMed

102.

Bal, M. M., Das Radotra, B., Srinivasan, R., & Sharma, S. C. (2006). Does c-erbB-2 expression have a role in medulloblastoma prognosis? Indian Journal of Pathology & Microbiology, 49(4), 535–539.

103.

Ivanov, D. P., Coyle, B., Walker, D. A., & Grabowska, A. M. (2016). In vitro models of medulloblastoma: choosing the right tool for the job. Journal of Biotechnology, 236, 10–25. https://doi.org/10.1016/j.jbiotec.2016.07.028.CrossRefPubMed

104.

Zeki, A. A., Yeganeh, B., Kenyon, N. J., & Ghavami, S. (2017). Editorial: new insights into a classical pathway: key roles of the mevalonate cascade in different diseases (part II). Current Molecular Pharmacology, 10(2), 74–76. https://doi.org/10.2174/187446721002170301204357.CrossRefPubMedPubMedCentral

105.

Matusewicz, L., Meissner, J., Toporkiewicz, M., & Sikorski, A. F. (2015). The effect of statins on cancer cells—review. Tumour Biology, 36(7), 4889–4904. https://doi.org/10.1007/s13277-015-3551-7.CrossRefPubMed

106.

Chan, K. K., Oza, A. M., & Siu, L. L. (2003). The statins as anticancer agents. Clinical Cancer Research, 9(1), 10–19.PubMed

107.

Bjarnadottir, O., Kimbung, S., Johansson, I., Veerla, S., Jonsson, M., Bendahl, P. O., et al. (2015). Global transcriptional changes following statin treatment in breast cancer. Clinical Cancer Research, 21(15), 3402–3411. https://doi.org/10.1158/1078-0432.ccr-14-1403.CrossRefPubMed

108.

Wang, T., Seah, S., Loh, X., Chan, C. W., Hartman, M., Goh, B. C., et al. (2016). Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget, 7(3), 2532–2544. https://doi.org/10.18632/oncotarget.6304.CrossRefPubMed

109.

de Bont, J. M., Packer, R. J., Michiels, E. M., den Boer, M. L., & Pieters, R. (2008). Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro-Oncology, 10(6), 1040–1060. https://doi.org/10.1215/15228517-2008-059.CrossRefPubMedPubMedCentral

110.

Cochrane, C. R., Szczepny, A., Watkins, D. N., & Cain, J. E. (2015). Hedgehog signaling in the maintenance of cancer stem cells. Cancers (Basel), 7(3), 1554–1585. https://doi.org/10.3390/cancers7030851.CrossRef

111.

Northcott, P. A., Dubuc, A. M., Pfister, S., & Taylor, M. D. (2012). Molecular subgroups of medulloblastoma. Expert Review of Neurotherapeutics, 12(7), 871–884. https://doi.org/10.1586/ern.12.66.CrossRefPubMedPubMedCentral

112.

Guerini, A. E., Triggiani, L., Maddalo, M., Bonu, M. L., Frassine, F., Baiguini, A., et al. (2019). Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers (Basel), 11(9). https://doi.org/10.3390/cancers11091284.

113.

Kohler, P. (2001). The biochemical basis of anthelmintic action and resistance. International Journal for Parasitology, 31(4), 336–345. https://doi.org/10.1016/s0020-7519(01)00131-x.CrossRefPubMed

114.

Goel, H. L., & Mercurio, A. M. (2013). VEGF targets the tumour cell. Nature Reviews. Cancer, 13(12), 871–882. https://doi.org/10.1038/nrc3627.CrossRefPubMedPubMedCentral

115.

Bai, R. Y., Staedtke, V., Wanjiku, T., Rudek, M. A., Joshi, A., Gallia, G. L., et al. (2015). Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clinical Cancer Research, 21(15), 3462–3470. https://doi.org/10.1158/1078-0432.ccr-14-2681.CrossRefPubMedPubMedCentral

116.

Rohatgi, R., Milenkovic, L., & Scott, M. P. (2007). Patched1 regulates hedgehog signaling at the primary cilium. Science, 317(5836), 372–376. https://doi.org/10.1126/science.1139740.CrossRefPubMed

117.

Yuen, G. J., Weller, S., & Pakes, G. E. (2008). A review of the pharmacokinetics of abacavir. Clinical Pharmacokinetics, 47(6), 351–371. https://doi.org/10.2165/00003088-200847060-00001.CrossRefPubMed

118.

Phatak, P., & Burger, A. M. (2007). Telomerase and its potential for therapeutic intervention. British Journal of Pharmacology, 152(7), 1003–1011. https://doi.org/10.1038/sj.bjp.0707374.CrossRefPubMedPubMedCentral

119.

Tendian, S. W., & Parker, W. B. (2000). Interaction of deoxyguanosine nucleotide analogs with human telomerase. Molecular Pharmacology, 57(4), 695–699. https://doi.org/10.1124/mol.57.4.695.CrossRefPubMed

120.

Shay, J. W., & Keith, W. N. (2008). Targeting telomerase for cancer therapeutics. British Journal of Cancer, 98(4), 677–683. https://doi.org/10.1038/sj.bjc.6604209.CrossRefPubMedPubMedCentral

121.

Chang, Q., Pang, J. C., Li, J., Hu, L., Kong, X., & Ng, H. K. (2004). Molecular analysis of PinX1 in medulloblastomas. International Journal of Cancer, 109(2), 309–314. https://doi.org/10.1002/ijc.11689.CrossRefPubMed

122.

Witzig, T. E., Timm, M., Stenson, M., Svingen, P. A., & Kaufmann, S. H. (2000). Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clinical Cancer Research, 6(2), 681–692.PubMed

123.

Shay, J. W., & Wright, W. E. (2005). Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis, 26(5), 867–874. https://doi.org/10.1093/carcin/bgh296.CrossRefPubMed

124.

Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of Clinical Investigation, 107(3), 351–362. https://doi.org/10.1172/jci9940.CrossRefPubMedPubMedCentral

125.

Kim, K. W., Mutter, R. W., Cao, C., Albert, J. M., Shinohara, E. T., Sekhar, K. R., et al. (2006). Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Molecular Cancer Therapeutics, 5(11), 2659–2665. https://doi.org/10.1158/1535-7163.mct-06-0261.CrossRefPubMed

126.

Chen, K. H., Hsu, C. C., Song, W. S., Huang, C. S., Tsai, C. C., Kuo, C. D., et al. (2010). Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Child's Nervous System, 26(11), 1605–1612. https://doi.org/10.1007/s00381-010-1190-2.CrossRefPubMed

127.

Abdelrahim, M., Baker, C. H., Abbruzzese, J. L., & Safe, S. (2006). Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. Journal of the National Cancer Institute, 98(12), 855–868. https://doi.org/10.1093/jnci/djj232.CrossRefPubMed

128.

Shelake, S., Sankpal, U. T., Paul Bowman, W., Wise, M., Ray, A., & Basha, R. (2017). Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth. Investigational New Drugs, 35(2), 158–165. https://doi.org/10.1007/s10637-016-0417-9.CrossRefPubMed

129.

Yao, J. C., Wang, L., Wei, D., Gong, W., Hassan, M., Wu, T. T., et al. (2004). Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clinical Cancer Research, 10(12 Pt 1), 4109–4117. https://doi.org/10.1158/1078-0432.ccr-03-0628.CrossRefPubMed

130.

Patil, S., Sankpal, U. T., Hurtado, M., Bowman, W. P., Murray, J., Borgmann, K., et al. (2019). Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells. Gene, 705, 67–76. https://doi.org/10.1016/j.gene.2019.04.037.CrossRefPubMedPubMedCentral

131.

Colon, N. C., & Chung, D. H. (2011). Neuroblastoma. Advances in Pediatrics, 58(1), 297–311. https://doi.org/10.1016/j.yapd.2011.03.011.CrossRefPubMedPubMedCentral

132.

Zaatiti, H., Abdallah, J., Nasr, Z., Khazen, G., Sandler, A., & Abou-Antoun, T. J. (2018). Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. International Journal of Oncology, 52(3), 787–803. https://doi.org/10.3892/ijo.2018.4236.CrossRefPubMedPubMedCentral

133.

Abou-Antoun, T. J., Nazarian, J., Ghanem, A., Vukmanovic, S., & Sandler, A. D. (2018). Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: a possible explanation for radio-therapy resistance. PLoS One, 13(1), e0189711. https://doi.org/10.1371/journal.pone.0189711.CrossRefPubMedPubMedCentral

134.

Lopez-Barcons, L., Maurer, B. J., Kang, M. H., & Reynolds, C. P. (2017). P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. International Journal of Cancer, 141(2), 405–413. https://doi.org/10.1002/ijc.30706.CrossRefPubMed

135.

Michaelis, M., Agha, B., Rothweiler, F., Löschmann, N., Voges, Y., Mittelbronn, M., et al. (2015). Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Scientific Reports, 5, 8202–8202. https://doi.org/10.1038/srep08202.CrossRefPubMedPubMedCentral

136.

Zhong, X., Zhao, E., Tang, C., Zhang, W., Tan, J., Dong, Z., et al. (2016). Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo. Tumor Biology, 37(6), 7615–7623. https://doi.org/10.1007/s13277-015-4613-6.CrossRefPubMed

137.

Di Zanni, E., Bianchi, G., Ravazzolo, R., Raffaghello, L., Ceccherini, I., & Bachetti, T. (2017). Targeting of PHOX2B expression allows the identification of drugs effective in counteracting neuroblastoma cell growth. Oncotarget, 8(42), 72133–72146. https://doi.org/10.18632/oncotarget.19922.CrossRefPubMedPubMedCentral

138.

Aveic, S., Pantile, M., Polo, P., Sidarovich, V., De Mariano, M., Quattrone, A., et al. (2018). Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors. Cancer Cell International, 18, 63–63. https://doi.org/10.1186/s12935-018-0557-4.CrossRefPubMedPubMedCentral

139.

Saulnier Sholler, G. L., Kalkunte, S., Greenlaw, C., McCarten, K., & Forman, E. (2006). Antitumor activity of Nifurtimox observed in a patient with neuroblastoma. Journal of Pediatric Hematology/Oncology, 28(10).

140.

Saulnier Sholler, G. L., Brard, L., Straub, J. A., Dorf, L., Illeyne, S., Koto, K., et al. (2009). Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. Journal of Pediatric Hematology/Oncology, 31(3), 187–193. https://doi.org/10.1097/MPH.0b013e3181984d91.CrossRefPubMed

141.

Cabanillas Stanchi, K. M., Bruchelt, G., Handgretinger, R., & Holzer, U. (2015). Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma. Cancer Biology & Therapy, 16(9), 1353–1363. https://doi.org/10.1080/15384047.2015.1070987.CrossRef

142.

Kong, E., Zhu, J., Wu, W., Ren, H., Jiao, X., Wang, H., et al. (2019). Nifurtimox inhibits the progression of neuroblastoma in vivo. Journal of Cancer, 10(10), 2194–2204. https://doi.org/10.7150/jca.27851.CrossRefPubMedPubMedCentral

143.

Bassiri, H., Benavides, A., Haber, M., Gilmour, S. K., Norris, M. D., & Hogarty, M. D. (2015). Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Translational pediatrics, 4(3), 226–238. https://doi.org/10.3978/j.issn.2224-4336.2015.04.06.CrossRefPubMedPubMedCentral

144.

Lozier, A. M., Rich, M. E., Grawe, A. P., Peck, A. S., Zhao, P., Chang, A. T.-T., et al. (2015). Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget, 6(1), 196–206. https://doi.org/10.18632/oncotarget.2768.CrossRefPubMed

145.

Larsson, K., Kock, A., Idborg, H., Arsenian Henriksson, M., Martinsson, T., Johnsen, J. I., et al. (2015). COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proceedings of the National Academy of Sciences of the United States of America, 112(26), 8070–8075. https://doi.org/10.1073/pnas.1424355112.CrossRefPubMedPubMedCentral

146.

Mooney, M. R., Geerts, D., Kort, E. J., & Bachmann, A. S. (2019). Anti-tumor effect of sulfasalazine in neuroblastoma. Biochemical Pharmacology, 162, 237–249. https://doi.org/10.1016/j.bcp.2019.01.007.CrossRefPubMed

147.

Komar-Stossel, C., Gross, E., Dery, E., Corchia, N., Meir, K., Fried, I., et al. (2014). TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model—evaluation by MRI. PLoS One, 9(3), e90224–e90224. https://doi.org/10.1371/journal.pone.0090224.CrossRefPubMedPubMedCentral

148.

Campos-Arroyo, D., Maldonado, V., Bahena, I., Quintanar, V., Patiño, N., Carlos Martinez-Lazcano, J., et al. (2016). Probenecid sensitizes neuroblastoma cancer stem cells to cisplatin. Cancer Investigation, 34(3), 155–166. https://doi.org/10.3109/07357907.2016.1139717.CrossRefPubMed

149.

Rodríguez-Hernández, C. J., Mateo-Lozano, S., García, M., Casalà, C., Briansó, F., Castrejón, N., et al. (2016). Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget, 7(13), 16112–16129. https://doi.org/10.18632/oncotarget.7448.CrossRefPubMedPubMedCentral

150.

Nishio, N., Fujita, M., Tanaka, Y., Maki, H., Zhang, R., Hirosawa, T., et al. (2012). Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. Journal of Immunotherapy, 35(8).

151.

Alizadeh, J., Zeki, A. A., Mirzaei, N., Tewary, S., Rezaei Moghadam, A., Glogowska, A., et al. (2017). Mevalonate Cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Scientific Reports, 7, 44841–44841. https://doi.org/10.1038/srep44841.CrossRefPubMedPubMedCentral

152.

Su, C., Shi, A., Cao, G., Tao, T., Chen, R., Hu, Z., et al. (2015). Fenofibrate suppressed proliferation and migration of human neuroblastoma cells via oxidative stress dependent of TXNIP upregulation. Biochemical and Biophysical Research Communications, 460(4), 983–988. https://doi.org/10.1016/j.bbrc.2015.03.138.CrossRefPubMed

153.

Costa, D., Gigoni, A., Würth, R., Cancedda, R., Florio, T., & Pagano, A. (2014). Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell International, 14, 59–59. https://doi.org/10.1186/1475-2867-14-59.CrossRefPubMedPubMedCentral

154.

Kumar, A., Al-Sammarraie, N., DiPette, D. J., & Singh, U. S. (2014). Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. Oncotarget, 5(22), 11709–11722. https://doi.org/10.18632/oncotarget.2606.CrossRefPubMedPubMedCentral

155.

Vujic, I., Sanlorenzo, M., Posch, C., Esteve-Puig, R., Yen, A. J., Kwong, A., et al. (2015). Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget, 6(2), 969–978. https://doi.org/10.18632/oncotarget.2824.CrossRefPubMed

156.

Mouhieddine, T. H., Nokkari, A., Itani, M. M., Chamaa, F., Bahmad, H., Monzer, A., et al. (2015). Metformin and Ara-a effectively suppress brain cancer by targeting cancer stem/progenitor cells. Frontiers in Neuroscience, 9, 442–442. https://doi.org/10.3389/fnins.2015.00442.CrossRefPubMedPubMedCentral

157.

Binlateh, T., Tanasawet, S., Rattanaporn, O., Sukketsiri, W., & Hutamekalin, P. (2019). Metformin promotes neuronal differentiation via crosstalk between Cdk5 and Sox6 in neuroblastoma cells. Evidence-based complementary and alternative medicine : eCAM, 2019, 1765182–1765182. https://doi.org/10.1155/2019/1765182.CrossRef

158.

Vella, S., Conaldi, P. G., Florio, T., & Pagano, A. (2016). PPAR gamma in neuroblastoma: the translational perspectives of hypoglycemic drugs. PPAR Research, 2016, 3038164–3038164. https://doi.org/10.1155/2016/3038164.CrossRefPubMedPubMedCentral

159.

Wolter, J. K., Wolter, N. E., Blanch, A., Partridge, T., Cheng, L., Morgenstern, D. A., et al. (2014). Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget, 5(1), 161–172. https://doi.org/10.18632/oncotarget.1083.CrossRefPubMed

160.

Vella, S., Penna, I., Longo, L., Pioggia, G., Garbati, P., Florio, T., et al. (2015). Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA. Scientific Reports, 5, 18144–18144. https://doi.org/10.1038/srep18144.CrossRefPubMedPubMedCentral

161.

Gu, S., Tian, Y., Chlenski, A., Salwen, H. R., Lu, Z., Raj, J. U., et al. (2012). Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma. Anti-Cancer Drugs, 23(10), 1054–1066. https://doi.org/10.1097/CAD.0b013e32835739dd.CrossRefPubMedPubMedCentral

162.

Shah, R. D., Jagtap, J. C., Mruthyunjaya, S., Shelke, G. V., Pujari, R., Das, G., et al. (2013). Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition. Journal of Cellular Biochemistry, 114(4), 854–863. https://doi.org/10.1002/jcb.24422.CrossRefPubMed

163.

Groh, T., Hrabeta, J., Ashraf Khalil, M., Doktorova, H., Eckschlager, T., & Stiborova, M. (2015). The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. International Journal of Oncology, 47(1), 343–352.CrossRefPubMed

164.

Fang, E., Wang, J., Hong, M., Zheng, L., & Tong, Q. (2019). Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma. Biochemical and Biophysical Research Communications, 508(1), 9–16. https://doi.org/10.1016/j.bbrc.2018.11.103.CrossRefPubMed

165.

Bayat Mokhtari, R., Baluch, N., Ka Hon Tsui, M., Kumar, S., S Homayouni, T., Aitken, K., et al. (2017). Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer, 17(1), 156–156, https://doi.org/10.1186/s12885-017-3126-7.

166.

Bilir, A., Erguven, M., Yazihan, N., Aktas, E., Oktem, G., & Sabanci, A. (2010). Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. Journal of Neuro-Oncology, 100(3), 385–395. https://doi.org/10.1007/s11060-010-0209-6.CrossRefPubMed

167.

Zheng, X., Naiditch, J., Czurylo, M., Jie, C., Lautz, T., Clark, S., et al. (2013). Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics. Cell Death & Disease, 4(7), e740–e740. https://doi.org/10.1038/cddis.2013.264.CrossRef

168.

Sidarovich, V., De Mariano, M., Aveic, S., Pancher, M., Adami, V., Gatto, P., et al. (2018). A high-content screening of anticancer compounds suggests the multiple tyrosine kinase inhibitor Ponatinib for repurposing in neuroblastoma therapy. Molecular Cancer Therapeutics, 17(7), 1405–1415. https://doi.org/10.1158/1535-7163.mct-17-0841.CrossRefPubMed

169.

Bahmad, H. F., Mouhieddine, T. H., Chalhoub, R. M., Assi, S., Araji, T., Chamaa, F., et al. (2018). The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma. Oncotarget, 9(71), 33549-33561, https://doi.org/10.18632/oncotarget.26088.

170.

Cerna, T., Hrabeta, J., Eckschlager, T., Frei, E., Schmeiser, H. H., Arlt, V. M., et al. (2018). The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug Ellipticine in neuroblastoma cells. International Journal of Molecular Sciences, 19(1), 164. https://doi.org/10.3390/ijms19010164.CrossRefPubMedCentral

171.

Chen, Y. U. N., Tsai, Y.-H., & Tseng, S.-H. (2011). Combined Valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. Anticancer Research, 31(6), 2231–2239.PubMed

172.

He, W., Wu, Y., Tang, X., Xia, Y., He, G., Min, Z., et al. (2016). HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells. Oncotarget, 7(6), 6727–6747. https://doi.org/10.18632/oncotarget.6797.CrossRefPubMed

173.

Dedoni, S., Marras, L., Olianas, M. C., Ingianni, A., & Onali, P. (2019). Downregulation of TrkB expression and signaling by Valproic acid and other histone deacetylase inhibitors. Journal of Pharmacology and Experimental Therapeutics, 370(3), 490. https://doi.org/10.1124/jpet.119.258129.CrossRefPubMed

174.

Khalil, M. A., Hraběta, J., Groh, T., Procházka, P., Doktorová, H., & Eckschlager, T. (2016). Valproic acid increases CD133 positive cells that show low sensitivity to cytostatics in neuroblastoma. PLoS One, 11(9), e0162916–e0162916. https://doi.org/10.1371/journal.pone.0162916.CrossRefPubMedPubMedCentral

175.

Lange, I., Espinoza-Fuenzalida, I., Ali, M. W., Serrano, L. E., & Koomoa, D.-L. T. (2017). FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways. Oncotarget, 8(66), 109985–109999. https://doi.org/10.18632/oncotarget.22452.CrossRefPubMedPubMedCentral

176.

Kanno, H., Nishihara, H., Oikawa, M., Ozaki, Y., Murata, J., Sawamura, Y., et al. (2012). Expression of O6-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors. Neuropathology, 32(6), 647–653. https://doi.org/10.1111/j.1440-1789.2012.01315.x.CrossRefPubMed

177.

DeBoer, R., Batjer, H., Marymont, M., Goldman, S., Walker, M., Gottardi-Littell, N., et al. (2009). Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. Journal of Neuro-Oncology, 95(2), 289–292. https://doi.org/10.1007/s11060-009-9921-5.CrossRefPubMed

178.

Mohankumar, K. M., Currle, D. S., White, E., Boulos, N., Dapper, J., Eden, C., et al. (2015). An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. Nature Genetics, 47(8), 878–887. https://doi.org/10.1038/ng.3323.CrossRefPubMedPubMedCentral

179.

Nimmervoll, B. V., Boulos, N., Bianski, B., Dapper, J., DeCuypere, M., Shelat, A., et al. (2018). Establishing a preclinical multidisciplinary board for brain tumors. Clinical Cancer Research, 24(7), 1654. https://doi.org/10.1158/1078-0432.CCR-17-2168.CrossRefPubMedPubMedCentral

Title: Drug repurposing towards targeting cancer stem cells in pediatric brain tumors
Authors: Hisham F. Bahmad
Mohamad K. Elajami
Talal El Zarif
Jolie Bou-Gharios
Tamara Abou-Antoun
Wassim Abou-Kheir
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Glioblastoma
Glioma
Medulloblastoma
Neuroblastoma
Neuroblastoma
Medulloblastoma
Glioma
Glioblastoma
Mebendazole
Medulloblastoma
Brain Tumor
Glioblastoma
Glioma
Published in: Cancer and Metastasis Reviews / Issue 1/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09840-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Preface

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches

Signaling pathways in Rhabdomyosarcoma invasion and metastasis

Correction to: Neurological complications of pediatric cancer

Mouse models of high-risk neuroblastoma

New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer